1
|
Li X, Jia F, Zhu Z, Huang L. Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes. Artif Cells Nanomed Biotechnol 2019; 47:1256-1264. [PMID: 30942623 DOI: 10.1080/21691401.2019.1593996] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Osteoarthritis (OA) poses a growing threat to the health of the global population. Accumulation of advanced glycation end-products (AGEs) has been shown to upregulate expression of degradative enzymes such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) in chondrocytes, which leads to excessive degradation of type II collagen and aggrecan in the articular extracellular matrix (ECM). In the present study we investigated the effects of the GLP-1 agonist lixisenatide, a widely used type II diabetes medication, on AGEs-induced decreased mitochondrial membrane potential (MMP), degradation of ECM, oxidative stress, expression of cytokines including interleukin (IL)-1β and IL-6, and activation of nuclear factor kappa B (NF-κB). Our findings indicate that lixisenatide significantly ameliorated the deleterious effects of AGEs in a dose-dependent manner. Thus, lixisenatide has potential as a safe and effective treatment for OA and other AGEs-induced inflammatory diseases.
Collapse
Affiliation(s)
- Xin Li
- a Department of Orthopaedics , The Second Hospital of Jilin University , Changchun , Jilin , China
| | - Fangteng Jia
- a Department of Orthopaedics , The Second Hospital of Jilin University , Changchun , Jilin , China
| | - Zhengqing Zhu
- a Department of Orthopaedics , The Second Hospital of Jilin University , Changchun , Jilin , China
| | - Lanfeng Huang
- a Department of Orthopaedics , The Second Hospital of Jilin University , Changchun , Jilin , China
| |
Collapse
|
2
|
Zhu S, Gu Y, Wang W, Bai J, Ge G, Zhang W, Wang Q, Guo X, Xiao L, Tao Y, Niu F, Nie Z, Geng D, Wang Z. Sitagliptin ameliorates advanced glycation end-product (AGE)-induced degradation of extracellular matrix in human primary chondrocytes. Am J Transl Res 2019; 11:2775-2783. [PMID: 31217853 PMCID: PMC6556674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Accepted: 01/19/2019] [Indexed: 06/09/2023]
Abstract
Accumulation of advanced glycation end-products (AGEs) increases inflammation and triggers processes involved in the pathogenesis of osteoarthritis (OA). As a major debilitating age-related disease, it is imperative that novel therapies for OA be sought. In the present study, we investigated the effects of the selective dipeptidyl peptidase IV (DPP-4) inhibitor sitagliptin in human primary chondrocytes exposed to insult by AGEs to elucidate the potential role of sitagliptin in the treatment of OA. Our findings show that inhibition of DPP-4 by sitagliptin could reduce oxidative stress, increase cell viability and prevent degradation of type II collagen and aggrecan by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) induced by AGEs in human primary chondrocytes. Mechanistically, we found that sitagliptin inhibited AGEs-induced nuclear translocation of p65 protein and drastically decreased the luciferase activity of NF-κB. These findings indicate that sitagliptin may have potential as a novel therapeutic option for the treatment and prevention of OA.
Collapse
Affiliation(s)
- Shijun Zhu
- Department of Ortopaedics, Affiliated Jining NO.1 People’s Hospital of Jining Medical University, Jining Medical UniversityJining 272011, China
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Ye Gu
- Department of Orthopedics, Changshu Hospital Affiliated to Soochow University, First People’s Hospital of Changshu CityChangshu 215500, China
| | - Wei Wang
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Jiaxiang Bai
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Gaorang Ge
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Wenhao Zhang
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Qing Wang
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Xiaobin Guo
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Long Xiao
- Department of Orthopaedics, Zhangjiagang Hospital of Traditional Chinese MedicineSuzhou 215600, China
| | - Yunxia Tao
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Fuwen Niu
- Department of Ortopaedics, Affiliated Jining NO.1 People’s Hospital of Jining Medical University, Jining Medical UniversityJining 272011, China
| | - Zhikui Nie
- Department of Ortopaedics, Affiliated Jining NO.1 People’s Hospital of Jining Medical University, Jining Medical UniversityJining 272011, China
| | - Dechun Geng
- Department of Orthopedics, The First Affiliated Hospital of Soochow UniversitySuzhou 215006, China
| | - Zhirong Wang
- Department of Orthopaedics, Zhangjiagang Hospital of Traditional Chinese MedicineSuzhou 215600, China
| |
Collapse
|
3
|
Abstract
The major limitations for cardiac regeneration in patients after myocardial infarction (MI) are the wide loss of cardiomyocytes and the adverse structural alterations of extracellular matrix (ECM). Cardiac fibroblast differentiation into myofibroblasts (MFB) leads to a huge deposition of ECM and to the subsequent loss of ventricular structural integrity. All these molecular events depict the fundamental features at the basis of the post-MI fibrosis and deserve in depth cellular and molecular studies to fill the gap in the clinical practice. Indeed, to date, there are no effective therapeutic approaches to limit the post-MI massive fibrosis development. In this review we describe the involvement of integrins and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)/ADAMTS-like (ADAMTSL) proteins in cardiac reparative pro-fibrotic response after MI, proposing some of them as novel potential pharmacological tools.
Collapse
Affiliation(s)
- Gianluca Lorenzo Perrucci
- Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milano, Italy.,Unità di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino-IRCCS, Milano, Italy
| | - Erica Rurali
- Unità di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino-IRCCS, Milano, Italy
| | - Giulio Pompilio
- Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milano, Italy.,Unità di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino-IRCCS, Milano, Italy.,Dipartimento di Chirurgia Cardiovascolare, Centro Cardiologico Monzino-IRCCS, Milano, Italy
| |
Collapse
|